Selpercatinib (Selpacta) 40mg/80mg — RET-Driven Cancer | GLT

Generic Info

Selpercatinib is an oral, highly selective RET kinase inhibitor. This product is marketed as Selpacta and manufactured by Ziska Pharmaceuticals Limited (Bangladesh). Selpercatinib was first approved by the U.S. FDA in 2020 as the first therapy specifically targeting RET-driven cancers. Selpacta is a generic version of selpercatinib offered at a more accessible price.

What Is Selpercatinib Used For?

Selpercatinib is used to treat cancers driven by RET gene alterations — specifically RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer, and other RET fusion-positive solid tumors. It is given only after a test confirms the presence of a RET fusion or mutation.

How Does Selpercatinib Work?

RET is a receptor tyrosine kinase that, when altered by a gene fusion or mutation, drives uncontrolled cancer cell growth. Selpercatinib is a highly selective RET kinase inhibitor: it binds and blocks RET, shutting down the downstream signaling that fuels tumor growth. Because it crosses the blood-brain barrier, it is effective against brain metastases — a key advantage for patients with central nervous system involvement.

Indications

• RET fusion-positive locally advanced or metastatic NSCLC
• RET-mutant advanced or metastatic medullary thyroid cancer (MTC)
• RET fusion-positive advanced or metastatic thyroid cancer (radioactive iodine-refractory, when applicable)
• RET fusion-positive locally advanced or metastatic solid tumors

Dosage

The recommended dose of selpercatinib in adults and adolescents 12 years and older is based on body weight: 120 mg orally twice daily for patients under 50 kg, and 160 mg orally twice daily for patients 50 kg or greater, until disease progression or unacceptable toxicity. Capsules/tablets are available in 40 mg, 80 mg, 120 mg, and 160 mg strengths. Dose reductions are required for severe hepatic impairment.

Side Effects

The most common side effects of selpercatinib include:

• Dry mouth
• Diarrhea
• Hypertension (high blood pressure)
• Fatigue
• Edema (swelling)
• Constipation
• Rash
• Elevated liver enzymes (ALT/AST)

Serious side effects include hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, and hypersensitivity reactions. Liver function and blood pressure should be monitored regularly during treatment.

Storage

Store selpercatinib at room temperature (20°C to 25°C / 68°F to 77°F). Keep in the original container, tightly closed, and out of reach of children. Do not use after the expiration date printed on the package.

Why Choose the GLT?

GIVE LIFE TIME LIMITED (GLT) sources genuine, manufacturer-sealed Selpacta (selpercatinib) and ships internationally with reliable logistics. We support both institutional buyers (hospitals, pharmacies, distributors) and individual patients, with responsive customer service and clear ordering guidance throughout the process.

How to Order

Contact our team via WhatsApp or email to confirm current availability, pricing, and shipping options for your region. Provide the required strength and quantity, and we will guide you through the ordering and delivery process.

FAQ

Q: Is Selpacta a chemotherapy?
No. Selpercatinib is a targeted therapy (a RET kinase inhibitor), not a conventional chemotherapy.

Q: Who can take Selpacta?
It is for patients whose cancer has a confirmed RET gene fusion or RET mutation, as detected by a molecular test.

Q: How is Selpacta taken?
It is taken orally, twice daily, with the dose based on body weight (120 mg or 160 mg twice daily for adults).